Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione
Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione
ESC 2017
Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione
BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study
BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study
ESC 2017
BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study
- Dr. Wilko Spiering
Novel insights in the management and prognosis of pulmonary hypertension
Novel insights in the management and prognosis of pulmonary hypertension
ESC 2017
Novel insights in the management and prognosis of pulmonary hypertension
- Prof Nazzareno Galiè
New therapeutic options can make a difference for diabetic patients with high CV risk
New therapeutic options can make a difference for diabetic patients with high CV risk
ESC 2017
New therapeutic options can make a difference for diabetic patients with high CV risk
- Prof. John E Deanfield, MD